These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34398356)

  • 41. The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom.
    Skoura E; Michopoulou S; Mohmaduvesh M; Panagiotidis E; Al Harbi M; Toumpanakis C; Almukhailed O; Kayani I; Syed R; Navalkissoor S; Ell PJ; Caplin ME; Bomanji J
    J Nucl Med; 2016 Jan; 57(1):34-40. PubMed ID: 26471695
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
    Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
    J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of Tumor Burden on Quantitative [
    Werner RA; Hänscheid H; Leal JP; Javadi MS; Higuchi T; Lodge MA; Buck AK; Pomper MG; Lapa C; Rowe SP
    Mol Imaging Biol; 2019 Aug; 21(4):790-798. PubMed ID: 30406512
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Single-time-point estimation of absorbed doses in PRRT using a non-linear mixed-effects model.
    Hardiansyah D; Riana A; Beer AJ; Glatting G
    Z Med Phys; 2023 Feb; 33(1):70-81. PubMed ID: 35961809
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
    Parghane RV; Talole S; Prabhash K; Basu S
    Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Standardized uptake values and ratios on 68Ga-DOTATATE PET-computed tomography for normal organs and malignant lesions and their correlation with Krenning score in patients with metastatic neuroendocrine tumors.
    Menon BK; Kalshetty A; Bhattacharjee A; Basu S
    Nucl Med Commun; 2020 Oct; 41(10):1095-1099. PubMed ID: 32732598
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predicting the effect of different folate doses on [
    Siebinga H; Hendrikx JJMA; Huitema ADR; de Wit-van der Veen BJ
    EJNMMI Res; 2023 Jun; 13(1):60. PubMed ID: 37318681
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management.
    Kunikowska J; Lewington V; Krolicki L
    Clin Nucl Med; 2017 Dec; 42(12):905-911. PubMed ID: 29076910
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biodistribution, Pharmacokinetics, and Dosimetry of
    Nicolas GP; Mansi R; McDougall L; Kaufmann J; Bouterfa H; Wild D; Fani M
    J Nucl Med; 2017 Sep; 58(9):1435-1441. PubMed ID: 28450554
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients.
    Sandström M; Lindskog K; Velikyan I; Wennborg A; Feldwisch J; Sandberg D; Tolmachev V; Orlova A; Sörensen J; Carlsson J; Lindman H; Lubberink M
    J Nucl Med; 2016 Jun; 57(6):867-71. PubMed ID: 26912439
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
    Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A
    Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety, Biodistribution, and Radiation Dosimetry of
    Nicolas GP; Beykan S; Bouterfa H; Kaufmann J; Bauman A; Lassmann M; Reubi JC; Rivier JEF; Maecke HR; Fani M; Wild D
    J Nucl Med; 2018 Jun; 59(6):909-914. PubMed ID: 29025985
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dosimetric analyses of kidneys, liver, spleen, pituitary gland, and neuroendocrine tumors of patients treated with 177Lu-DOTATATE.
    Gupta SK; Singla S; Thakral P; Bal CS
    Clin Nucl Med; 2013 Mar; 38(3):188-94. PubMed ID: 23412597
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic value of somatostatin receptor expressing tumor volume calculated from
    Toriihara A; Baratto L; Nobashi T; Park S; Hatami N; Davidzon G; Kunz PL; Iagaru A
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2244-2251. PubMed ID: 31350603
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study.
    Pfeifer A; Knigge U; Mortensen J; Oturai P; Berthelsen AK; Loft A; Binderup T; Rasmussen P; Elema D; Klausen TL; Holm S; von Benzon E; Højgaard L; Kjaer A
    J Nucl Med; 2012 Aug; 53(8):1207-15. PubMed ID: 22782315
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Time-integrated activity coefficient estimation for radionuclide therapy using PET and a pharmacokinetic model: A simulation study on the effect of sampling schedule and noise.
    Hardiansyah D; Guo W; Kletting P; Mottaghy FM; Glatting G
    Med Phys; 2016 Sep; 43(9):5145. PubMed ID: 27587044
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Head-to-Head Comparison of
    Johnbeck CB; Knigge U; Loft A; Berthelsen AK; Mortensen J; Oturai P; Langer SW; Elema DR; Kjaer A
    J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Rate and Clinical Significance of Incidental Thyroid Uptake as Detected by Gallium-68 DOTATATE Positron Emission Tomography/Computed Tomography.
    Nockel P; Millo C; Keutgen X; Klubo-Gwiezdzinska J; Shell J; Patel D; Nilubol N; Herscovitch P; Sadowski SM; Kebebew E
    Thyroid; 2016 Jun; 26(6):831-5. PubMed ID: 27094616
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of baseline Ga-68 DOTATATE positron emission tomography/computed tomography in the prediction of response to fixed-dose peptide receptor radionuclide therapy with Lu-177 DOTATATE.
    Soydal Ç; Peker A; Özkan E; Küçük ÖN; Kir MK
    Turk J Med Sci; 2016 Feb; 46(2):409-13. PubMed ID: 27511504
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A frequency and semiquantitative analysis of pathological 68Ga DOTATATE PET/CT uptake by primary site-dependent neuroendocrine tumor metastasis.
    Kunikowska J; Pawlak D; Kolasa A; Mikołajczak R; Królicki L
    Clin Nucl Med; 2014 Oct; 39(10):855-61. PubMed ID: 25072928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.